search
Back to results

Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis

Primary Purpose

Osteoporosis

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Parathyroid hormone (hPTH 1-34)
Sponsored by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoporosis focused on measuring Parathyroid hormone (1-34), Glucocorticoid-induced osteoporosis, Postmenopausal women, osteoporotic fractures

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Postmenopausal women on glucocorticoids (prednisone 5mg/d or greater Osteopenia by T score of hip or lumbar spine of -2.0 All study subjects must be on a stable dose of estrogen/progesterone or raloxifene Ambulatory and able to come to the clinical center 9 times over 2 years Willing to sign an informed consent Exclusion Criteria: Generalized disease of the bone (other than glucocorticoid-induced osteoporosis), including hyperparathyroidism, hyperthyroidism, Paget's disease) Diseases that affect bone metabolism (e.g. alcoholism, inflammatory bowel disease, malabsorption, renal disease (Cr2) or liver disease (transaminase level 2 times limit of normal) Within the past 1 year, regular use of medications that are known to affect bone metabolism (e.g. anabolic steroids, anticoagulants, anticonvulsants, pharmacologic doses of vitamin D and vitamin A supplements). History of drug abuse Senile dementia, paraplegia and/or quadriplegia Unstable rheumatic disease with clinically significant renal or central nervous system involvement.

Sites / Locations

  • San Francisco General Hospital

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
March 17, 2000
Last Updated
March 1, 2010
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT00004993
Brief Title
Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis
Official Title
Can PTH Reverse Glucocorticoid-induced Osteoporosis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2010
Overall Recruitment Status
Completed
Study Start Date
August 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 2001 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

5. Study Description

Brief Summary
Glucocorticoids are potent anti-inflammatory and immunosuppressive agents. However, prolonged use of these potent agents results in severe bone loss and osteoporotic fractures. Parathyroid hormone (1-34), when given as a daily injection has been found to dramatically increase bone mass in osteoporotic animals and postmenopausal women. The purpose of this study is to determine whether 2 years of daily PTH (1-34) injections will increase bone mass and reduce the development of new fractures. In addition, we will follow the study subjects for 2 more years to determine which type of anti-resorptive agent is required to maintain the newly formed bone. We are enrolling postmenopausal women that are on chronic corticosteroid therapy (prednisone etc.) and have bone loss (osteopenia by DXA) to be a part of this four-year-long study. The patients will receive two-year therapy with either PTH (1-34) or placebo, and for the second part of the study subjects receive either estrogen and placebo or alendronate and placebo. We will measure bone gain by standard bone densitometry, special x-rays of the spine and hip, and serum and urine bone markers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis
Keywords
Parathyroid hormone (1-34), Glucocorticoid-induced osteoporosis, Postmenopausal women, osteoporotic fractures

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Masking
Double
Allocation
Randomized

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Parathyroid hormone (hPTH 1-34)

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Postmenopausal women on glucocorticoids (prednisone 5mg/d or greater Osteopenia by T score of hip or lumbar spine of -2.0 All study subjects must be on a stable dose of estrogen/progesterone or raloxifene Ambulatory and able to come to the clinical center 9 times over 2 years Willing to sign an informed consent Exclusion Criteria: Generalized disease of the bone (other than glucocorticoid-induced osteoporosis), including hyperparathyroidism, hyperthyroidism, Paget's disease) Diseases that affect bone metabolism (e.g. alcoholism, inflammatory bowel disease, malabsorption, renal disease (Cr2) or liver disease (transaminase level 2 times limit of normal) Within the past 1 year, regular use of medications that are known to affect bone metabolism (e.g. anabolic steroids, anticoagulants, anticonvulsants, pharmacologic doses of vitamin D and vitamin A supplements). History of drug abuse Senile dementia, paraplegia and/or quadriplegia Unstable rheumatic disease with clinically significant renal or central nervous system involvement.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Qaiser Rehman, M.D.
Organizational Affiliation
University of California at San Francisco
Official's Role
Study Director
Facility Information:
Facility Name
San Francisco General Hospital
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
9788977
Citation
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998 Oct 15;102(8):1627-33. doi: 10.1172/JCI3914.
Results Reference
background

Learn more about this trial

Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis

We'll reach out to this number within 24 hrs